WebPlease refine your search by(Localization + What, who? ... Edit search Login / Register My account WebMay 26, 2024 · Afami-cel is a cell therapy that uses a patient's own T-cells to express an engineered T-cell receptor (TCR) designed to kill cancer cells in solid tumors expressing a protein called MAGE-A4
Novel T cell receptor therapy shows early anti-tumor activity
WebJan 9, 2024 · Afami-cel is an investigational, engineered T-cell receptor (TCR) T-cell therapy targeting the cancer testis antigen MAGE-A4 which is expressed across multiple solid tumor indications. WebJun 2, 2024 · Background: Afami-cel is an autologous, HLA-A*02-restricted, specific peptide enhanced affinity receptor, T-cell therapy engineered to target MAGE-A4+ solid tumors. The pivotal, 2-cohort, single-arm, Phase 2, SPEARHEAD-1 trial (NCT04044768) with afami-cel met its primary endpoint based on Cohort 1 data. tahiti must see travel
Clinical Responses Reported across Patient Subgroups with …
WebJan 9, 2024 · Afamitresgene autoleucel (afami-cel) is an autologous, specific peptide enhanced affinity receptor, T cell therapy transduced via a lentiviral vector to express a … WebNov 12, 2024 · Radiation sub-study (closed to enrollment in July 2024) of the Phase 1 trial with afami-cel As of December 27, 2024 (data cut-off), 4 patients received low-dose radiation and afami-cel Overall response rate was 33%, 1 partial response (PR) (melanoma; reported in 2024) out of 3 evaluable patients WebNov 19, 2024 · Afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics) has demonstrated continued clinical responses in patients with late-stage synovial sarcoma in the phase 2 SPEARHEAD-1 study (NCT04044768). 1 These new data were presented in an oral presentation at the Connective Tissue Oncology Society (CTOS) annual meeting … breadboard\\u0027s ja